Reema Jasuja

Biography

Reema Jasuja, PhD, is a Principle Scientist in Pfizer’s Rare Disease Research Unit. Dr. Jasuja joined Pfizer in Cambridge, MA in 2012, and contributed to efforts in hematology projects across the Rare Disease Research Unit, including sickle cell disease and hemophilia. She has worked extensively with in vivo models of both hemophilia and sickle cell disease. Dr. Jasuja did the preclinical work around Tissue Factor Pathway Inhibitor, which achieved Proof-of-Mechanism in 2016 for prophylaxis in hemophilia. She has also worked extensively across sickle cell disease projects including preclinical studies on PDE9 inhibitor for sickle cell disease. Additionally, she is the research program lead of an early stage program on Erythroferrone antibody, for managing iron overload in patients with thalassemia and other rare forms of anemias leading to iron overload. Dr. Jasuja did her graduate work in molecular and cellular pharmacology at University of Wisconsin- Madison with Dr. Daniel Greenspan. She studied extracellular signaling regulation of Bone morphogenetic protein 1 and how the prodomain of Bone morphogenetic protein 1regulates the protein activity to affect downstream signaling mechanisms. Her postdoctoral work at the Beth Israel Deaconess Medical Center, Harvard Medical School with Drs. Barbara and Bruce Furie focused on hemostasis and thrombosis regulation by extracellular protein disulfide isomerase and other thiol isomerases. During her postdoctoral work, she was involved in using a novel technology of using intravital microscopy, and she has now brought this technology for preclinical models within Pfizer. Reema Jasuja, PhD, is a Principle Scientist in Pfizer’s Rare Disease Research Unit. Dr. Jasuja joined Pfizer in Cambridge, MA in 2012, and contributed to efforts in hematology projects across the Rare Disease Research Unit, including sickle cell disease and hemophilia. She has worked extensively with in vivo models of both hemophilia and sickle cell disease. Dr. Jasuja did the preclinical work around Tissue Factor Pathway Inhibitor, which achieved Proof-of-Mechanism in 2016 for prophylaxis in hemophilia. She has also worked extensively across sickle cell disease projects including preclinical studies on PDE9 inhibitor for sickle cell disease. Additionally, she is the research program lead of an early stage program on Erythroferrone antibody, for managing iron overload in patients with thalassemia and other rare forms of anemias leading to iron overload. Dr. Jasuja did her graduate work in molecular and cellular pharmacology at University of Wisconsin- Madison with Dr. Daniel Greenspan. She studied extracellular signaling regulation of Bone morphogenetic protein 1 and how the prodomain of Bone morphogenetic protein 1regulates the protein activity to affect downstream signaling mechanisms. Her postdoctoral work at the Beth Israel Deaconess Medical Center, Harvard Medical School with Drs. Barbara and Bruce Furie focused on hemostasis and thrombosis regulation by extracellular protein disulfide isomerase and other thiol isomerases. During her postdoctoral work, she was involved in using a novel technology of using intravital microscopy, and she has now brought this technology for preclinical models within Pfizer.

Research Interest

Clinical data management, Clinical trails, Pharmacovigilance